Most insulin secretagogues in clinical treatment for controlling glycemia, such as sulfonylureas, increase insulin secretion in a glucose-independent manner, which means they may stimulate insulin secretion even under low-glucose conditions; they therefore carry a high risk of hypoglycemia incidents (Hayward, et al., 1997), which is a common and even fatal complications in diabetes treatment (Frier, et al., 2011). Here, INS is linked to Hypoglycemia.